NDSI
CRMD icon

Newman Dignan & Sheerar Inc’s CorMedix CRMD Stock Holding History

Newman Dignan & Sheerar Inc’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,282
Closed -$92K – 168
2020
Q3 		$92K Buy
+15,282
New +$76.7K 0.04% 163

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Newman Dignan & Sheerar Inc's CRMD Position: Q4 2020 in Review

Newman Dignan & Sheerar Inc sold out of CorMedix (CRMD) in Q4 2020, closing a stake of 15,282 shares — an estimated $92K sold.

Newman Dignan & Sheerar Inc first reported a position in CRMD in Q3 2020 and held it in 1 quarter. The position peaked at $92K in Q3 2020. 75 funds tracked by Wall St. Rank hold CRMD as of Q4 2020.

  • Newman Dignan & Sheerar Inc reported no remaining CorMedix position as of Q4 2020 after selling out during the quarter.
  • Newman Dignan & Sheerar Inc sold 15,282 CorMedix shares in Q4 2020, an estimated $92K.
  • Newman Dignan & Sheerar Inc first reported a position in CorMedix in Q3 2020 and held it in 1 quarter.
  • Newman Dignan & Sheerar Inc's CorMedix position peaked at $92K in Q3 2020.
  • 75 funds tracked by Wall St. Rank held CorMedix as of Q4 2020.

Based on Newman Dignan & Sheerar Inc's 13F filing for Q4 2020, filed 29 Jan 2021.